A Phase 1b/2 clinical trial of SNB-101, targeting patients diagnosed with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs SNB 101 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 16 Jan 2025 New trial record
- 10 Jan 2025 SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for this Phase 1b/2 clinical trial.
- 10 Jan 2025 According to the SN BioScience Media Release, this study aimed at supporting Phase 2 clearance in Europe.